Quizartinib
From Wikipedia, the free encyclopedia
Jump to navigation
Jump to search
Quizartinib
|
Names
|
---|
IUPAC name
1-(5-(tert-Butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea
|
Other names
AC220
|
Identifiers
|
---|
CAS Number
|
950769-58-1 Y
|
3D model (JSmol)
|
|
ChEBI
|
CHEBI:90217 N
|
ChEMBL
|
ChEMBL576982 N
|
ChemSpider
|
24640357 N
|
IUPHAR/BPS
|
|
KEGG
|
|
UNII
|
7LA4O6Q0D3 Y
|
InChI InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36) NKey: CVWXJKQAOSCOAB-UHFFFAOYSA-N N
InChI=1/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36) Key: CVWXJKQAOSCOAB-UHFFFAOYAF
|
SMILES CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6
|
Properties
|
---|
Chemical formula
|
C29H32N6O4S
|
Molar mass
|
560.67 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
N verify (what is YN ?)
|
Infobox references
|
|
|
Quizartinib (AC220) is a small molecule receptor tyrosine kinase inhibitor that is currently under development by Ambit Biosciences for the treatment of acute myeloid leukaemia. Its molecular target is FLT3, also known as CD135 which is a proto-oncogene.[1]
Flt3 mutations are among the most common mutations in acute myeloid leukaemia due to internal tandem duplication of Flt3. The presence of this mutation is a marker of adverse outcome.
Mechanism[edit]
Specifically, Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs).[citation needed]
Mutations cause constitutive action of Flt3 resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis.[citation needed]
Clinical trials[edit]
It reported good results in 2012 from a phase II clinical trial for refractory AML - particularly in patients who went on to have a stem cell transplant.[2]
As of 2017[update] it has completed 5 clinical trials and another 7 are active.[3]
References[edit]
^ Chao, Qi; Sprankle, Kelly G.; Grotzfeld, Robert M.; Lai, Andiliy G.; Carter, Todd A.; Velasco, Anne Marie; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; James, Joyce; Zarrinkar, Patrick P.; Patel, Hitesh K.; Bhagwat, Shripad S. (2009). "Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenylurea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor". Journal of Medicinal Chemistry. 52 (23): 7808–7816. doi:10.1021/jm9007533..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em
^ Drug Tames Refractory AML. ASH Dec 2012
^ Quizartinib studies
Cytokine receptor modulators
|
---|
Chemokine |
|
---|
CSF |
Erythropoietin |
Agonists: ARA-290
- Asialo erythropoietin
- Carbamylated erythropoietin
- CNTO-530
- Darbepoetin alfa
- Epoetin alfa
- Epoetin beta
- Epoetin delta
- Epoetin epsilon
- Epoetin gamma
- Epoetin kappa
- Epoetin omega
- Epoetin theta
- Epoetin zeta
- Erythropoietin (EPO)
- Erythropoietin-Fc
- Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)
- Peginesatide
- Pegol sihematide (EPO-018B)
|
---|
G-CSF (CSF3) |
Agonists: Filgrastim
- Granulocyte colony-stimulating factor
- Lenograstim
- Leridistim
- Lipegfilgrastim
- Nartograstim
- Pegfilgrastim
- Pegnartograstim
|
---|
GM-CSF (CSF2) |
Agonists: Ecogramostim
- Granulocyte macrophage colony-stimulating factor
- Milodistim
- Molgramostim
- Regramostim
- Sargramostim
Antibodies: Mavrilimumab
- MOR103
- Namilumab
|
---|
M-CSF (CSF1) |
Agonists: Cilmostim
- Interleukin-34
- Lanimostim
- Macrophage colony-stimulating factor
- Mirimostim
Kinase inhibitors: Agerafenib
|
---|
SCF (c-Kit) |
|
---|
Thrombopoietin |
Agonists: Eltrombopag
- Pegacaristim
- Promegapoietin
- Romiplostim
- Thrombopoietin (THPO, MGDF)
|
---|
|
---|
Interferon |
IFNAR (α/β, I) |
Agonists: Albinterferon
- Interferon alpha (interferon alfa, IFN-α)
Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)
- Interferon alfa 2a
- Interferon alfa 2b
- Interferon alfa n1
- Interferon alfacon-1
- Interferon alpha-n3
Interferon beta (IFN-β) (IFNB1, IFNB3)
- Interferon beta 1a
- Interferon beta 1b
- Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)
- Interferon omega (IFN-ω, IFNW1)
- Peginterferon alfa-2a
- Peginterferon alfa-2b
Antibodies: Anifrolumab
- Faralimomab
- MEDI-545
- Rontalizumab
- Sifalimumab
Decoy receptors: Bifarcept
|
---|
IFNGR (γ, II) |
Agonists: Interferon gamma (IFN-γ)
- Interferon gamma 1b
Antibodies: Emapalumab
- Fontolizumab
|
---|
IFNLR (λ, III) |
- See IL-28R (IFNLR) here instead.
|
---|
|
---|
Interleukin |
|
---|
TGFβ |
|
---|
TNF |
|
---|
Others |
JAK (inhibitors)
|
JAK1 |
- Baricitinib
- Filgotinib
- Momelotinib
- Oclacitinib
- Ruxolitinib
- Tofacitinib (tasocitinib, CP-690550)
- Upadacitinib
|
---|
JAK2 |
- AG-490
- Atiprimod
- AZD-1480
- Baricitinib
- CHZ868
- Cucurbitacin I (elatericin B, JSI-124)
- CYT387
- Lestaurtinib
- NSC-7908
- NSC-33994
- Pacritinib
- Ruxolitinib
- SD-1008
- Tofacitinib (tasocitinib, CP-690550)
|
---|
JAK3 |
- AG-490
- Cercosporamide
- TCS-21311
- Tofacitinib (tasocitinib, CP-690550)
- WHI-P 154
- ZM-39923
- ZM-449829
|
---|
|
---|
Others |
Additional cytokines: Cardiotrophin 1 (CT-1)
- FMS-like tyrosine kinase 3 ligand (FLT3L)
- Leukemia/leukocyte inhibitory factor (LIF)
- Oncostatin M (OSM)
- Thymic stromal lymphopoietin (TSLP)
Additional cytokine receptor modulators: Emfilermin
- Lestaurtinib
- Midostaurin
- Quizartinib
- Sorafenib
- Sunitinib
|
---|
|
---|
- See also
- Receptor/signaling modulators
- Signaling peptide/protein receptor modulators
- Growth factor receptor modulators
|
Growth factor receptor modulators
|
---|
Angiopoietin |
Agonists: Angiopoietin 1
- Angiopoietin 4
Antagonists: Angiopoietin 2
- Angiopoietin 3
Kinase inhibitors: Altiratinib
- CE-245677
- Rebastinib
Antibodies: Evinacumab (against angiopoietin 3)
Nesvacumab (against angiopoietin 2)
|
---|
CNTF |
Agonists: Axokine
- CNTF
- Dapiclermin
|
---|
EGF (ErbB) |
EGF (ErbB1/HER1)
|
Agonists: Amphiregulin
- Betacellulin
- EGF (urogastrone)
- Epigen
- Epiregulin
- Heparin-binding EGF-like growth factor (HB-EGF)
- Murodermin
- Nepidermin
- Transforming growth factor alpha (TGFα)
Kinase inhibitors: Afatinib
- AG-490
- Agerafenib
- Brigatinib
- Canertinib
- Dacomitinib
- Erlotinib
- Gefitinib
- Grandinin
- Icotinib
- Lapatinib
- Neratinib
- Osimertinib
- Vandetanib
- WHI-P 154
Antibodies: Cetuximab
- Depatuxizumab
- Depatuxizumab mafodotin
- Futuximab
- Imgatuzumab
- Matuzumab
- Necitumumab
- Nimotuzumab
- Panitumumab
- Zalutumumab
|
---|
ErbB2/HER2 |
Antibodies: Ertumaxomab
- Pertuzumab
- Trastuzumab
- Trastuzumab duocarmazine
- Trastuzumab emtansine
Kinase inhibitors: Afatinib
- AG-490
- Lapatinib
- Mubritinib
- Neratinib
|
---|
ErbB3/HER3 |
Agonists: Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))
Antibodies: Duligotumab
- Patritumab
- Seribantumab
|
---|
ErbB4/HER4 |
Agonists: Betacellulin
- Epigen
- Heparin-binding EGF-like growth factor (HB-EGF)
Neuregulins (heregulins) (1, 2, 3, 4, 5 (tomoregulin, TMEFF))
|
---|
|
---|
FGF |
FGFR1 |
Agonists: Ersofermin
FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
- Repifermin
- Trafermin
- Velafermin
|
---|
FGFR2 |
Agonists: Ersofermin
FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)
- Palifermin
- Repifermin
- Sprifermin
- Trafermin
Antibodies: Aprutumab
- Aprutumab ixadotin
|
---|
FGFR3 |
Agonists: Ersofermin
FGF (1, 2 (bFGF), 4, 8, 9, 18, 23)
- Sprifermin
- Trafermin
Antibodies: Burosumab (against FGF23)
|
---|
FGFR4 |
Agonists: Ersofermin
FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)
- Trafermin
|
---|
Unsorted |
|
---|
|
---|
HGF (c-Met) |
Agonists: Hepatocyte growth factor
Potentiators: Dihexa (PNB-0408)
Kinase inhibitors: Altiratinib
- AM7
- AMG-458
- Amuvatinib
- BMS-777607
- Cabozantinib
- Crizotinib
- Foretinib
- Golvatinib
- INCB28060
- JNJ-38877605
- K252a
- MK-2461
- PF-04217903
- PF-2341066
- PHA-665752
- SU-11274
- Tivantinib
- Volitinib
Antibodies: Emibetuzumab
- Ficlatuzumab
- Flanvotumab
- Onartuzumab
- Rilotumumab
- Telisotuzumab
- Telisotuzumab vedotin
|
---|
IGF |
IGF-1 |
Agonists: des(1-3)IGF-1
- Insulin-like growth factor-1 (somatomedin C)
- IGF-1 LR3
- Insulin-like growth factor-2 (somatomedin A)
- Insulin
- Mecasermin
- Mecasermin rinfabate
Kinase inhibitors: BMS-754807
- Linsitinib
- NVP-ADW742
- NVP-AEW541
- OSl-906
Antibodies: AVE-1642
- Cixutumumab
- Dalotuzumab
- Figitumumab
- Ganitumab
- Robatumumab
- R1507
- Teprotumumab
Xentuzumab (against IGF-1 and IGF-2)
|
---|
IGF-2 |
Agonists: Insulin-like growth factor-2 (somatomedin A)
Antibodies: Dusigitumab
Xentuzumab (against IGF-1 and IGF-2)
|
---|
Others |
Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7)
Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1)
- Trofinetide
|
---|
|
---|
LNGF (p75NTR) |
Agonists: BDNF
- BNN-20
- BNN-27
- Cenegermin
- DHEA
- DHEA-S
- NGF
- NT-3
- NT-4
Antagonists: ALE-0540
- Dexamethasone
- EVT-901 (SAR-127963)
- Testosterone
Antibodies: Against NGF: ABT-110 (PG110)
- ASP-6294
- Fasinumab
- Frunevetmab
- Fulranumab
- MEDI-578
- Ranevetmab
- Tanezumab
Aptamers: Against NGF: RBM-004
Decoy receptors: LEVI-04 (p75NTR-Fc)
|
---|
PDGF |
Agonists: Becaplermin
Platelet-derived growth factor (A, B, C, D)
Kinase inhibitors: Agerafenib
- Axitinib
- Crenolanib
- Imatinib
- Lenvatinib
- Masitinib
- Motesanib
- Nintedanib
- Pazopanib
- Radotinib
- Quizartinib
- Sunitinib
- Sorafenib
- Toceranib
Antibodies: Olaratumab
- Ramucirumab
- Tovetumab
|
---|
RET (GFL) |
GFRα1 |
Agonists: Glial cell line-derived neurotrophic factor (GDNF)
- Liatermin
Kinase inhibitors: Vandetanib
|
---|
GFRα2 |
Agonists: Neurturin (NRTN)
Kinase inhibitors: Vandetanib
|
---|
GFRα3 |
Kinase inhibitors: Vandetanib
|
---|
GFRα4 |
Agonists: Persephin (PSPN)
Kinase inhibitors: Vandetanib
|
---|
Unsorted |
Kinase inhibitors: Agerafenib
|
---|
|
---|
SCF (c-Kit) |
Agonists: Ancestim
- Stem cell factor
Kinase inhibitors: Agerafenib
- Axitinib
- Dasatinib
- Imatinib
- Masitinib
- Nilotinib
- Pazopanib
- Quizartinib
- Sorafenib
- Sunitinib
- Toceranib
|
---|
TGFβ |
|
---|
Trk |
TrkA |
Agonists: Amitriptyline
- BNN-20
- BNN-27
- Cenegermin
- DHEA
- DHEA-S
- Gambogic amide
- NGF
- Tavilermide
Antagonists: ALE-0540
- Dexamethasone
- FX007
- Testosterone
Negative allosteric modulators: VM-902A
Kinase inhibitors: Altiratinib
- AZD-6918
- CE-245677
- CH-7057288
- DS-6051
- Entrectinib
- GZ-389988
- K252a
- Larotrectinib
- Lestaurtinib
- Milciclib
- ONO-4474
- ONO-5390556
- PLX-7486
- Rebastinib
SNA-120 (pegylated K252a))
Antibodies: Against TrkA: GBR-900; Against NGF: ABT-110 (PG110)
- ASP-6294
- Fasinumab
- Frunevetmab
- Fulranumab
- MEDI-578
- Ranevetmab
- Tanezumab
Aptamers: Against NGF: RBM-004
Decoy receptors: ReN-1820 (TrkAd5)
|
---|
TrkB |
Agonists: 3,7-DHF
- 3,7,8,2'-THF
- 4'-DMA-7,8-DHF
- 7,3'-DHF
- 7,8-DHF
- 7,8,2'-THF
- 7,8,3'-THF
- Amitriptyline
- BDNF
- BNN-20
- Deoxygedunin
- Deprenyl
- Diosmetin
- DMAQ-B1
- HIOC
- LM22A-4
- N-Acetylserotonin
- NT-3
- NT-4
- Norwogonin (5,7,8-THF)
- R7
- R13
- TDP6
Antagonists: ANA-12
- Cyclotraxin B
- Gossypetin (3,5,7,8,3',4'-HHF)
Kinase inhibitors: Altiratinib
- AZD-6918
- CE-245677
- CH-7057288
- DS-6051
- Entrectinib
- GZ-389988
- K252a
- Larotrectinib
- Lestaurtinib
- ONO-4474
- ONO-5390556
- PLX-7486
|
---|
TrkC |
Kinase inhibitors: Altiratinib
- AZD-6918
- CE-245677
- CH-7057288
- DS-6051
- Entrectinib
- GZ-389988
- K252a
- Larotrectinib
- Lestaurtinib
- ONO-4474
- ONO-5390556
- PLX-7486
|
---|
|
---|
VEGF |
Agonists: Placental growth factor (PGF)
- Telbermin
VEGF (A, B, C, D (FIGF))
Allosteric modulators: Cyclotraxin B
Kinase inhibitors: Agerafenib
- Altiratinib
- Axitinib
- Cabozantinib
- Cediranib
- Lapatinib
- Lenvatinib
- Motesanib
- Nintedanib
- Pazopanib
- Pegaptanib
- Rebastinib
- Regorafenib
- Semaxanib
- Sorafenib
- Sunitinib
- Toceranib
- Tivozanib
- Vandetanib
- WHI-P 154
Antibodies: Alacizumab pegol
- Bevacizumab
- Icrucumab
- Ramucirumab
- Ranibizumab
Decoy receptors: Aflibercept
|
---|
Others |
Additional growth factors: Adrenomedullin
Colony-stimulating factors (see here instead)
- Connective tissue growth factor (CTGF)
Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)
Erythropoietin (see here instead)
- Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
- Glia maturation factor (GMF)
- Hepatoma-derived growth factor (HDGF)
Interleukins/T-cell growth factors (see here instead)
- Leukemia inhibitory factor (LIF)
- Macrophage-stimulating protein (MSP; HLP, HGFLP)
- Midkine (NEGF2)
- Migration-stimulating factor (MSF; PRG4)
- Oncomodulin
- Pituitary adenylate cyclase-activating peptide (PACAP)
- Pleiotrophin
- Renalase
Thrombopoietin (see here instead)
- Wnt signaling proteins
Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)
|
---|
- See also
- Receptor/signaling modulators
- Signaling peptide/protein receptor modulators
- Cytokine receptor modulators
|
Categories:
- Receptor tyrosine kinase inhibitors
- Morpholines
- Isoxazoles
- Ureas
- Tert-butyl compounds
Hidden categories:
- Chemicals without a PubChem CID
- Articles with changed EBI identifier
- Articles with changed ChemSpider identifier
- Articles with changed InChI identifier
- Articles containing unverified chemical infoboxes
- All articles with unsourced statements
- Articles with unsourced statements from December 2012
- Articles containing potentially dated statements from 2017
- All articles containing potentially dated statements
Navigation menu
Personal tools
- Not logged in
- Talk
- Contributions
- Create account
- Log in
Navigation
- Main page
- Contents
- Featured content
- Current events
- Random article
- Donate to Wikipedia
- Wikipedia store
Interaction
- Help
- About Wikipedia
- Community portal
- Recent changes
- Contact page
Tools
- What links here
- Related changes
- Upload file
- Special pages
- Permanent link
- Page information
- Wikidata item
- Cite this page
Print/export
- Create a book
- Download as PDF
- Printable version
Languages
- Српски / srpski
- Srpskohrvatski / српскохрватски
Edit links
(window.RLQ=window.RLQ||).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.664","walltime":"0.819","ppvisitednodes":"value":6358,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":223849,"limit":2097152,"templateargumentsize":"value":21653,"limit":2097152,"expansiondepth":"value":22,"limit":40,"expensivefunctioncount":"value":4,"limit":500,"unstrip-depth":"value":1,"limit":20,"unstrip-size":"value":4480,"limit":5000000,"entityaccesscount":"value":2,"limit":400,"timingprofile":["100.00% 608.504 1 -total"," 68.09% 414.304 1 Template:Chembox"," 38.39% 233.608 1 Template:Chembox_Identifiers"," 24.74% 150.530 3 Template:Chembox_headerbar"," 24.39% 148.400 9 Template:Trim"," 14.93% 90.823 10 Template:Main_other"," 14.69% 89.363 1 Template:Chembox_Properties"," 14.59% 88.767 1 Template:Reflist"," 13.13% 79.904 1 Template:Cite_journal"," 12.79% 77.819 1 Template:Chembox_parametercheck"],"scribunto":"limitreport-timeusage":"value":"0.229","limit":"10.000","limitreport-memusage":"value":4725237,"limit":52428800,"cachereport":"origin":"mw1271","timestamp":"20181010224750","ttl":1900800,"transientcontent":false);mw.config.set("wgBackendResponseTime":108,"wgHostname":"mw1320"););